Literature DB >> 21585382

Influence of atorvastatin on fractional and subfractional composition of serum lipoproteins and MMP activity in mice with Triton WR 1339-induced lipaemia.

Tatyana A Korolenko1, Marina S Cherkanova, Fedor V Tuzikov, Thomas P Johnston, Natalia A Tuzikova, Viktoriya M Loginova, Vassilij I Kaledin.   

Abstract

OBJECTIVES: The effects of atorvastatin on the atherogenic and anti-atherogenic lipoprotein-cholesterol (C-LP) and lipoprotein-triglyceride (TG-LP) fractions and subfractions at the early stage of murine acute hyperlipidaemia, and its pleiotropic anti-inflammatory effects via the activity of matrix metalloproteinases (MMPs) were studied.
METHODS: Atorvastatin (75 mg/kg) was administered to ICR mice with acute lipaemia induced by a single injection of Triton WR 1339 (500 mg/kg). A novel small-angle X-ray scattering (SAXS) method was used for the determination of the fractional and subfractional composition of C-LP and TG-LP. KEY FINDING: In Triton WR 1339-treated mice, there was a drastic increase in the atherogenic low-density C-LP (C-LDL) fraction, intermediate density lipoprotein-cholesterol (C-IDL) subfraction, and very low-density C-LP (C-VLDL) fractions (C-VLDL(3-5) subfraction). Additionally, there was an increase in the C-HDL(3) subfraction. Treatment of lipaemia with atorvastatin resulted in the normalization of the atherogenic C-LDL fraction and the C-IDL subfraction. A decrease in C-VLDL (C-VLDL(3-5) subfraction), total cholesterol and, especially, triglyceride (TG) concentrations was also demonstrated. Similar results were obtained with the TG-LP fractions and subfractions. Additionally, atorvastatin treatment resulted in an increase in the serum and liver MMP activity.
CONCLUSION: High-dose atorvastatin therapy exerts its rapid lipid-lowering and pleiotropic effect(s) in the early stages of acute lipaemia induced with Triton WR-1339.
© 2011 The Authors. JPP © 2011 Royal Pharmaceutical Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21585382     DOI: 10.1111/j.2042-7158.2011.01287.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  3 in total

1.  Effect of poloxamer 407 administration on the serum lipids profile, anxiety level and protease activity in the heart and liver of mice.

Authors:  Tatyana A Korolenko; Thomas P Johnston; Nina I Dubrovina; Yana A Kisarova; Svetlana Ya Zhanaeva; Marina S Cherkanova; Elena E Filjushina; Tatyana V Alexeenko; Eva Machova; Natalya A Zhukova
Journal:  Interdiscip Toxicol       Date:  2013-03

Review 2.  Hypolipidemic Effects of β-Glucans, Mannans, and Fucoidans: Mechanism of Action and Their Prospects for Clinical Application.

Authors:  Tatiana A Korolenko; Nataliya P Bgatova; Marina V Ovsyukova; Alexandra Shintyapina; Vaclav Vetvicka
Journal:  Molecules       Date:  2020-04-16       Impact factor: 4.411

3.  Early-stage atherosclerosis in poloxamer 407-induced hyperlipidemic mice: pathological features and changes in the lipid composition of serum lipoprotein fractions and subfractions.

Authors:  Tatyana A Korolenko; Thomas P Johnston; Fedor V Tuzikov; Natalia A Tuzikova; Alexandr B Pupyshev; Victor K Spiridonov; Natalya V Goncharova; Igor V Maiborodin; Natalia A Zhukova
Journal:  Lipids Health Dis       Date:  2016-01-22       Impact factor: 3.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.